Colon cancer metastasis blocked by curcumin
the ONA take:
According to new research published in the journal PLOS One, curcumin, a bioactive molecule derived from tumeric, can prevent colon cancer metastasis. Researchers from the University of Arizona's Steele Children's Research Center in Tucson, Arizona, curcumin inhibits cortacin, a protein necessary for cell movement, in colon cancer. Because cortacin is often overexpressed in cancer cells, it provides cancer cells with the ability to move and metastasize to other parts of the body.
The researchers discovered the active part of cortacin, Phospho Tyrosine 421 (pTyr421) to be overexpressed in malignant colon cancer cells. The malignant cancer cells were then treated with curcumin and found that curcumin inhibited pTyr421. Tus, the colon cancer cells lost their ability to spread and migrate.
This study lays the foundation for future studies involving curcumin to be conducted for the prevention of cancer metastasis. Eventually, drugs may be designed with curcumin to block colon cancer cells from spreading.
According to the Centers for Disease Control and Prevention (CDC), colorectal cancer is the second leading cause of cancer-related death of both men and women in the United States.
Curcumin, derived from the spice turmeric, blocks the protein cortactin in colon cancer.
Novel research led by the UA Steele Children's Research Center has identified one of the mechanisms by which curcumin, a bioactive molecule derived from the spice turmeric, can prevent cancer cell metastasis in colon cancer.
A team of researchers led by the University of Arizona's Steele Children's Research Center discovered that curcumin – the bioactive molecule derived from the spice turmeric – blocks the protein cortactin in colon cancer.
Cortactin, a protein essential for cell movement, frequently is overexpressed in cancer, thus facilitating cancer cell metastasis to other organs in the body.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|